Welcome to CDC Stacks | Low Rates of Bone Mineral Density Measurement in Medicare Beneficiaries with Prostate Cancer Initiating Androgen Deprivation Therapy - 30341 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Low Rates of Bone Mineral Density Measurement in Medicare Beneficiaries with Prostate Cancer Initiating Androgen Deprivation Therapy
Filetype[PDF - 389.27 KB]


Details:
  • Pubmed ID:
    24146343
  • Pubmed Central ID:
    PMC4369911
  • Funding:
    5U58/DP000824-05/DP/NCCDPHP CDC HHS/United States
    CA016672/CA/NCI NIH HHS/United States
    K24 AR053593/AR/NIAMS NIH HHS/United States
    K24 AR053593/AR/NIAMS NIH HHS/United States
    P30 CA016672/CA/NCI NIH HHS/United States
  • Document Type:
  • Collection(s):
  • Description:
    Background

    Men with prostate cancer who undergo androgen deprivation therapy (ADT) are at risk for bone loss and fractures. Our objective was to determine if Medicare beneficiaries with prostate cancer in the state of Texas underwent DXA scans when initiating ADT.

    Methods

    We identified men diagnosed with prostate cancer between 2005 and 2007 in the Texas Cancer Registry/Medicare linked database, and who received parenteral ADT or orchiectomy. We identified DXA claims within 1 year before or 6 months after starting ADT. We examined use of bone conservation agents in the subgroup of patients enrolled in Medicare Part D. Multivariate logistic regression models were used to examine determinants of DXA use.

    Results

    The analysis included 2,290 men (2,262 parenteral ADT, 28 orchiectomy): 197 (8.6%) underwent DXA within 1 year before and 6 months after starting ADT. Men aged 75 years or older were more likely to undergo DXA than men aged 66-74 years (OR:1.5; 95%CI:1.1-2.1). Those living in small urban areas were less likely to undergo DXA than those in big areas (OR:0.40; 95%CI:0.19-0.82). Of the 1,060 men enrolled in Medicare Part D, 59 (5.6%) received bone conservation agents when starting ADT; 134 (12.6%) either received bone conservation agents or underwent DXA.

    Conclusions

    Fewer than 1 in 10 Medicare beneficiaries with prostate cancer initiating ADT underwent a DXA exam. Variation in utilization was also related to residence area size. Further research is needed to identify whether the use of DXA in patients with prostate cancer receiving ADT will result in fracture prevention.